Toll Free (US):+1(800)9439753

Kisqali

Kisqali contains the active ingredient ribociclib, which is a type of drug called a CDK4/6 inhibitor.

This product is currently out of stock and unavailable.

Added to wishlistRemoved from wishlist 0
Add to compare
The orders are shipped to almost all countries of the worlds Including USA, Canada, United Kingdom and EU countries.
Express: 5-9 business days
Standard: 10-21 days
SKU: 89747 Category:

Kisqali – Ribociclib – 200mg

  • Brand: Kryxana
  • Manufacturer:
  • Disease: Cancer

Kisqali (ribociclib) is a prescription medicine that is used to treat:

-postmenopausal women with hormone receptor positive, HER2 negative advanced or metastatic breast cancer

-women who have been treated with antihormone therapy (e.g., tamoxifen, aromatase inhibitors) and are now having their disease progression

It works by slowing down the activity of two proteins called CDK4 and CDK6, which are involved in the growth of cancer cells.

The recommended dose of Kisqali for treating postmenopausal women with hormone receptor positive advanced or metastatic breast cancer is 600 mg taken as three 200 mg tablets once daily for 21 consecutive days followed by 7 days off treatment. The recommended dose for treating premenopausal women who have not gone through menopause yet but whose disease has progressed after treatment with antihormone therapy is 400 mg taken as two 200 mg tablets once daily on Days 1 to 21 of each 28 day cycle


Frequently asked Questions

How much does Kisqali cost in Canada?

Kisqali belongs to a class of medications called CDK4/6 inhibitors. It works by slowing the growth of cancer cells.

Before you start taking Kisqali, be sure to tell your doctor if you have any other medical conditions, especially those that may affect how your body absorbs or uses drugs. You should also let your doctor know if you are pregnant or breastfeeding, as Kisqali may not be safe for use in these cases.

Take Kisqali exactly as prescribed by your doctor. Do not stop taking it without first talking to your healthcare provider. Possible side effects include diarrhea, nausea, and vomiting. Let your doctor know if these symptoms are severe or bothersome.

Although there are many potential treatments for breast cancer currently available on the market today- one such treatment gaining attention recently is Ribociclib (trade name: Kiskali). This novel drug was FDA approved in March of 2017 specifically for postmenopausal women with hormone receptor positive – HER2 negative metastatic breast cancer who have had no prior anti-cancer therapy1. The mode of action behind ribociclib’s efficacy against tumors relies on its inhibition of cyclin dependent kinases 4 and 6 (CDK4/6), which play an important role in regulating cell division – leading ultimately tumor regression 1. The benefits associated with this new drug don’t come without risk however; common adverse effects seen among patients during clinical trials included neutropenia (low white blood cell count), leukopenia( low red blood cell count), anemia, thrombocytopenia( low platelet levels ) and diarrhea 2 Ribociclib has been shown to prolong progression free survival rates when used concurrently with endocrine therapy3 ; making it a potentially valuable tool against some forms aggressive estrogen receptor positive cancers 3


How long has Kisqali been on the market?

Kisqali is also approved for the treatment of premenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with tamoxifen and an aromatase inhibitor.

In clinical studies, Kisqali was shown to delay disease progression and extend survival compared to placebo. In patients receiving Kisqali plus letrozole versus placebo plus letrozole, median progression free survival was not reached in either arm after 24 months of follow up; however, the hazard ratio indicated that patients taking Kisqali were more likely to experience delayed disease progression (HR=0.61 [95% CI: 0.47–0.79]). The addition of ribociclib to endocrine therapy improved overall response rate by 44% versus endocrine therapy alone (ORR=44% [95% CI: 34%, 54%]), including complete responses observed in 7 percent of patients treated with ribociclib plus endocrine therapy versus 0 percent treated with endocrine therapy alone


How much longer can you live taking Kisqali?

Kisqali belongs to a group of medicines called CDK4/6 inhibitors. It works by slowing the growth of tumor cells.

Kisqali was approved by the U.S. Food and Drug Administration in March 2017 for use in combination with an aromatase inhibitor as initial therapy for postmenopausal women with hormone receptor positive, HER2 negative advanced or metastatic breast cancer. Kisqali is also approved in more than 60 countries worldwide, including the European Union, Canada and Australia, for this same indication


Is Kisqali better than Verzenio?

Kisqali is used to treat advanced or metastatic breast cancer in women who have gone through menopause. It is also used to treat advanced or metastatic hormone-receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer in postmenopausal women with disease progression after endocrine therapy. Kisqali may be given alone or together with other medicines for treatment of these cancers.

Kisqali belongs to a group of medicines called kinase inhibitors. These work by blocking some proteins that help tumor cells grow and divide. This can slow or stop the spread of tumor cells throughout the body


What does Kisqali do to your body?


Does Kisqali cause weight gain?

Kisqali belongs to a group of medicines called kinase inhibitors. These work by blocking some proteins that help tumor cells grow and divide. This can slow or stop the spread of tumor cells throughout the body

Kisqali is approved by the U.S. Food and Drug Administration (FDA) for use in combination with an aromatase inhibitor, such as letrozole, for postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced or metastatic breast cancer who have not received prior therapy for their advanced disease. Kisqali belongs to a class of medications called CDK4/6 inhibitors that work by blocking enzymes called cyclin-dependent kinases 4 and 6, which can help slow the growth of cancer cells.

Before taking Kisqali, tell your doctor if you have ever had: liver problems; heart problems; high blood pressure; a stroke; seizures; diabetes; or are pregnant or breastfeeding. Tell your doctor about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements because some may interact with Kisqali causing serious side effects including low white blood cell counts and QT prolongation (a type of abnormal heartbeat rhythm). Do not drink grapefruit juice while taking Kisqali as it may increase your risk of side effects from the medicine.

Kisquali is an amazing new addition to treatment options for those suffering from Breast Cancer It has been shown to be very effective when used in combination with other treatments such as Letrozole. I would recommend anyone diagnosed with Breast Cancer ask their oncologist about using this drug in their treatment plan.


When is the best time of day to take Kisqali?

Kisqali is used to treat advanced breast cancer in women who have gone through menopause. It is also used to treat advanced ovarian cancer. Kisqali may be given alone or with other medicines.

Some common side effects of Kisqali include: tiredness, nausea, vomiting, diarrhea, constipation, hair loss, and headache. These are not all of the possible side effects of Kisqali. Tell your doctor if you have any side effect that bothers you or does not go away.


Why can't you eat grapefruit while taking Kisqali?

Kisqali belongs to a group of drugs called CDK4/6 inhibitors. It works by slowing the growth of cancer cells.

Before you start taking Kisqali, tell your doctor if you have ever had: liver disease; heart disease; high blood pressure; stroke; problems with your kidneys or gallbladder; seizures or epilepsy; diabetes mellitus (sugar diabetes); anemia (a lack of red blood cells); any type of infection including tuberculosis, herpes virus, and HIV/AIDS infection.

Take Kisqali exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label carefully. Swallow the tablet whole with water. Do not crush, chew, break,or dissolve the tablet before swallowing it. You may take Kisqali with food if it upsets your stomach. If you vomit after taking this medication, do not take another dose until 12 hours have passed since vomiting occurred. Contact your doctor if vomiting continues more often than once every 3 days while taking this medicine..

KISQALI is indicated as monotherapy for treatment of postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer who have received prior endocrine therapy


Does Kisqali cause diarrhea?

Kisqali is used in combination with an aromatase inhibitor.

Kisqali was approved by the U.S. Food and Drug Administration on March 13, 2017, as a first-line treatment for postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor based on results from the MONALEESA-7 clinical trial. Kisqali plus letrozole reduced the risk of disease progression or death by 44 percent compared to letrozole alone . The most common side effects of Kisqali include neutropenia, diarrhea, nausea and vomiting, headache and fatigue .

Breast cancer is the second leading cause of cancer death among American women, yet many people are not aware that there are treatments available beyond surgery and radiation therapy. Each year since 2002[4], more than 200,000 women have been diagnosed with breast cancer in the United States alone[5]. While early stage tumors can often be treated successfully through surgery alone, more than two thirds of all patients who are diagnosed with late stage or metastatic disease will eventually die from their illness[6],[7],[8],[9],[10].

Fortunately progress has been made over recent years in developing new treatments for advanced stages of breast cancer including therapies that target specific molecules within tumor cells known as receptors. One such class of drugs called CDK inhibitors blocks enzymes known as cyclin dependent kinases 4 and 6 (CDK4/6), which promote tumor cell growth [11][12][13][14][15]. One drug in this class – ribociclib – was recently approved by the FDA for use alongside another medication called an aromatase inhibitor for postmenopausal patients with HR+/HER2− advanced or metastatic breast cancer who have not received prior chemotherapy treatment for their disease. In clinical trials involving over 1 000 patients, ribociclib extended median progression free survival time from 9·3 months to 14·7 months when added to endocrine therapy regimens containing either fulvestrant ou tamoxifen citrate; it also improved objective response rates significantly compared to placebo arm


When was Kisqali FDA approved?

Kisqali belongs to a group of medicines called CDK4/6 inhibitors. It works by blocking the activity of 2 proteins called CDK4 and CDK6, which are involved in the growth and spread of cancer cells.

This medication comes as a tablet that you take by mouth. It is usually taken once per day with or without food. Take Kisqali at around the same time every day. Do not crush or chew this medication, as it may cause irritation in your mouth or throat. Swallow it whole with water.</p>

<p>Your doctor will likely tell you to take Kisqali for at least 3 years.</p>

<p>Some common side effects of Kisqali include:</p><ul><li>nausea</li><li>[http://www1.uspharmacist.com/drug_information/featured_drugs/kisqaliribociclibhtml?ref=hp&utm_source=zergnet&utm_medium=referral&utm_campaign=#sideeffects vomiting]</li><li>[http://www1.uspharmacist.com / drug _ information / featured _ drugs / kis q ali ribociclibh tml?ref = hp & utm _ source = zergnet & utm _ medium = referral & utm _ campaign=#sideeffects diarrhea] </ li >< li > fatigue </ li >< li > headache </ li >< li > joint pain </ ul >< p > Tell your doctor if you experience any serious side effects, including: signs of infection such as fever, chills, body aches; easy bruising or bleeding; severe stomach pain; chest pain; shortness of breath; swelling in your hands or feet.</ p></ div></ div></ blockquote

Specification: Kisqali

Quantity

Dosage

User Reviews

0.0 out of 5
0
0
0
0
0
Write a review

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

24healthgoods.com
Logo
Compare items
  • Total (0)
Compare
0
Shopping cart